Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04373044
Recruitment Status : Recruiting
First Posted : May 4, 2020
Last Update Posted : May 21, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.

Condition or disease Intervention/treatment Phase
Symptomatic COVID-19 Infection Laboratory-Confirmed Drug: Baricitinib Drug: Hydroxychloroquine Drug: Placebo Administration Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. To determine the efficacy of baricitinib combined with antiviral therapy in participants with COVID-19-related moderate and severe disease in terms of reduction of the proportion of participants requiring invasive mechanical ventilation or dying or requiring anti-IL6 monoclonal antibodies compared to that seen with antiviral alone within 60 days.

SECONDARY OBJECTIVES:

I. To describe the clinical findings in a cohort of symptomatic COVID-19-infected participants.

II. To test whether cytokine signatures predict progression to invasive ventilatory support or death.

III. To describe adverse events (AEs) associated with baricitinib when administered at 4mg in combination with antivirals.

EXPLORATORY OBJECTIVES:

I. Describe the decay in quantitative viral burden from saliva samples collected sequentially under treatment with baricitinib in combination with antivirals.

II. To obtain preliminary data on efficacy and tolerability of baricitinib in combination with antivirals in participants with cancer.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive baricitinib orally (PO) daily, and standard of care hydroxychloroquine PO three times daily (TID). Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.

GROUP II: Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for 60 days after enrollment to treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Actual Study Start Date : April 24, 2020
Estimated Primary Completion Date : April 24, 2021
Estimated Study Completion Date : April 24, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Arm II (placebo, antiviral therapy)
Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Drug: Hydroxychloroquine
Given PO

Drug: Placebo Administration
Given Po

Experimental: Treatment (baricitinib, antiviral therapy)
Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Drug: Baricitinib
Given PO
Other Names:
  • INCB 028050
  • INCB028050
  • LY 3009104
  • LY3009104

Drug: Hydroxychloroquine
Given PO




Primary Outcome Measures :
  1. Proportion of patients requiring invasive mechanical ventilation or dying [ Time Frame: Up to 14 days ]
    Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic coronavirus disease 2019 (COVID-19)-infected subjects. The collected data will also be graphically presented in boxplots, histograms, and scatter plots. Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made. Group comparisons will be made using either the parametric tests such as t-test and analysis of variance (ANOVA), or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables. Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.


Secondary Outcome Measures :
  1. Identification of clinical features (vitals signs - body temperature) [ Time Frame: Up to 28 days ]
    Body temperature will be measured in degrees Fahrenheit using an automated thermometer.

  2. Identification of clinical features (vital signs - respiratory rate) [ Time Frame: Up to 28 days ]
    Respiratory rate in times/minute

  3. Identification of clinical features (vital signs - heart rate) [ Time Frame: Up to 28 days ]
    Heart rate in beats/minute

  4. Identification of clinical features (vital signs - blood pressure) [ Time Frame: Up to 28 days ]
    Blood pressure in mmHg

  5. Identification of clinical features (Imaging) [ Time Frame: Up to 28 days ]
    Chest X-ray or pulmonary computed tomography (CT) will be performed

  6. Identification of clinical features (Lab - White Blood Count) [ Time Frame: Up to 28 days ]
    Assessment via standard blood chemistry and metabolic panel

  7. Identification of clinical features (Lab - Absolute Lymphocyte Count) [ Time Frame: Up to 28 days ]
    Assessment via standard blood chemistry and metabolic panel

  8. Identification of clinical features (Lab - Hemoglobin) [ Time Frame: Up to 28 days ]
    Assessment via standard blood chemistry and metabolic panel

  9. Identification of clinical features (Lab - Creatinine) [ Time Frame: Up to 28 days ]
    Assessment via standard blood chemistry and metabolic panel

  10. Identification of biomarkers (C-reactive protein) [ Time Frame: Up to 14 days ]
    CRP is assessed by routinely used determination of CRP.

  11. Identification of biomarkers (Interleukin-6) [ Time Frame: Up to 14 days ]
    IL-6 levels will be assessed using commercial ELISA method

  12. Identification of biomarkers (Tumor Necrosis Factor-alpha) [ Time Frame: Up to 14 days ]
    Tumor Necrosis Factor-alpha as measured in hospital laboratory

  13. Identification of adverse events [ Time Frame: Up to 14 days ]
    Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic COVID-19-infected subjects. The collected data will also be graphically presented in boxplots, histograms, and scatter plots. Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made. Group comparisons will be made using either the parametric tests such as t-test and ANOVA, or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables. Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.


Other Outcome Measures:
  1. Measurement of COVID19 viral burden [ Time Frame: Up to 14 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in a respiratory tract sample OR positive anti-SARS CoV2 IgM antibody test that is approved by Food and Drug Administration (FDA) or allowed under an emergency use authorization; either result obtained within 5 days prior to study entry
  • Cough and/or pneumonia on chest imaging
  • Moderate disease with risk factor(s): Peripheral capillary oxygen saturation (SpO2) >= 92% on room air with one of the following risk factors for development of severe disease: age >= 60 years, receiving medication for hypertension, diagnosed diabetes mellitus, known cardiac disease, chronic lung disease, obesity (body mass index [BMI] >= 35 kg/m^2), active malignancy, immunosuppression (receiving biologics or glucocorticoids >= 20 mg/d prednisone equivalent for > 2 weeks)
  • Severe disease: SpO2 =< 92% on room air
  • Ability to understand and the willingness to sign a written informed consent. Adults not competent to consent will be enrolled with the use of an appropriate legally authorized representative (per California Code, Health and Safety Code - HSC)

    • FDA regulations generally require that the informed consent of a participant be documented by the use of a written consent form approved by the IRB and signed and dated by the participant or the participant's legally authorized representative at the time of consent (21 case form report [CFR] 50.27[a]). In light of COVID-19 infection control measures, the following procedure would satisfy documentation of this requirement if the participant signing the informed consent is in COVID-19 isolation. If the technology is available, electronic methods of obtaining informed consent will be taken. The electronic consent and Health Insurance Portability and Accountability Act (HIPAA) forms will be uploaded and available through REDCap
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential should use highly effective methods of birth control. These are those methods of contraception, alone or in combination, that result in a low failure rate (i.e, less than 1% per year) when used consistently and correctly

Exclusion Criteria:

  • Mechanical ventilation, high-flow nasal oxygen, biphasic positive airway pressure (BiPAP)
  • Venous thromboembolism within 12 weeks or previously diagnosed thrombophilic conditions or conditions that increase the risk of thrombosis. Individuals with > 1 episode of venous thromboembolism or pulmonary embolism in the past will also be excluded
  • Prior receipt of other immunomodulatory drugs (e.g., any JAK inhibitors, immunomodulatory biologics, or other immunomodulatory investigational products) within 14 days prior to enrollment
  • Current treatment with probenecid
  • Known infection with human immunodeficiency syndrome (HIV), or active infection with hepatitis B or hepatitis C
  • Participant with known active or latent tuberculosis infection
  • Pregnancy and lactation
  • Any serious acute infections or known active or latent tuberculosis

    • All enrolled participants will be screened for latent tuberculosis infection by testing QuantiFERON-TB Gold Plus, but a documented negative test will not be required prior to entry. If a participant is found to have positive QuantiFERON that results after enrollment, baricitinib will be discontinued
  • Solid organ transplant recipient
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal
  • Absolute neutrophil count < 1000/mm^3
  • Absolute lymphocyte count < 200/mm^3
  • Hemoglobin < 8 g/dl
  • Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2
  • Any medical condition in the opinion of the investigator that would place the participant at undue high risk for participation in the trial
  • Hypersensitivity to the active substance or to any of the excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04373044


Contacts
Layout table for location contacts
Contact: Tali Homsey, BA (323) 273-8338 Tali.Homsey@med.usc.edu

Locations
Layout table for location information
United States, California
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Tali Homsey, BA    323-273-8338    Tali.Homsey@med.usc.edu   
Principal Investigator: Heinz-Josef Lenz, MD         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Heinz-Josef Lenz    323-865-3955    Lenz@usc.edu   
Principal Investigator: Heinz-Josef Lenz         
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Heinz-Josef Lenz, MD University of Southern California

Layout table for additonal information
Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT04373044    
Other Study ID Numbers: 0S-20-3
NCI-2020-02685 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
0S-20-3 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Posted: May 4, 2020    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Laboratory Infection
Infection
Occupational Diseases
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents